TET2 mutations were found in 14 out of 71 patients (20%), including 13/60 patients with an aggressive subtype (acute+lymphoma) and 1/11 patient with indolent subtype (chronic+smoldering) (Table 2 and Figure 3A). This evidence concerns the gene TET2 and lymphoma.